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Epigenetic dysregulation of the Drp1 binding partners MiD49 and MiD51 increases mitotic 
mitochondrial fission and promotes pulmonary arterial hypertension: mechanistic and 
therapeutic implications 
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Abstract  (Word count: 385) 
Background: Mitotic fission is increased in hyperproliferative, apoptosis-resistant diseases, such as 
pulmonary arterial hypertension (PAH). The fission mediator, dynamin related protein 1 (Drp1) must 
complex with adaptor proteins to cause fission. Drp1-induced fission has been therapeutically targeted 
in experimental PAH. Here we examine the role of two recently discovered, poorly understood, Drp1 
adapter proteins, mitochondrial dynamics protein of 49 and 51 kDa (MiD49 and MiD51) in normal 
vascular cells and explore their dysregulation in PAH. 
Methods: Immunoblots of pulmonary artery smooth muscle cells (PASMC, n=6 for control vs n=8 for 
PAH patients) and immunohistochemistry of lung sections (n=6 each for control and PAH patients) 
were used to assess the expression of MiD49 and MiD51. The effects of manipulating MiDs on cell 
proliferation, cell cycle, and apoptosis were assessed in human and rodent PAH PASMC using flow 
cytometry. Mitochondrial fission was studied in live cells by confocal imaging using complimentary 
probes and mitochondrial morphology was quantified by a machine-learning algorithm. A microRNA 
(miR) involved in the regulation of MiD expression was identified using in silico analyses and 
microarray techniques. The expression of circulatory miR was assessed using qRT-PCR in healthy 
volunteers (HV) vs PAH patients from Sheffield, UK (HV=29, PAH= 27 for plasma; HV=11, PAH= 14 
for whole blood), and then confirmed in a cohort from Beijing, China (HV=19, PAH= 36 for plasma; 
HV=20, PAH= 39 for whole blood), This work was replicated in monocrotaline and SU5416-hypoxia, 
preclinical PAH models. siRNA targeting MiDs or a miR mimic were nebulized to rats with 
monocrotaline-induced PAH (n=4-10). 
Results: MiD expression is increased in PAH PASMC. Increased MiD expression accelerates Drp1-
mediated mitotic fission, increases cell proliferation and decreases apoptosis. Silencing MiDs (but not 
other Drp1 binding partners, Fis1 or MFF) promotes mitochondrial fusion and causes G1-phase cell 
cycle arrest, through an ERK1/2 and CDK4-dependent mechanism. Results were concordant in human 
and experimental PAH. Augmenting MiDs in normal cells causes fission and recapitulates the PAH 
phenotype. MiD upregulation results from decreased miR-34a-3p expression. Circulatory miR-34a-3p 
3	
expression is decreased in PAH patients as well as in preclinical models of PAH. Silencing MiDs or 
augmenting miR-34a-3p regresses experimental PAH. 
Conclusion: In health, MiDs regulate Drp1-mediated fission whilst in disease, epigenetic upregulation 
of MiDs increases mitotic fission, which drives pathologic proliferation and apoptosis resistance. The 
miR-34a-3p-MiD pathway offers new therapeutic targets for PAH.  
 
Key Words: mitochondrial dynamics, mitochondrial fission, extracellular signal regulated kinase 
(ERK), cyclin dependent kinase (CDK), dynamin related protein 1 (Drp1), miR-34a-3p, cell cycle 
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CLINICAL PERSPECTIVE 1	
 2	
What is New? Word count: 100 3	
 4	
 5	
¥ We identify a key role for MiD49 and MiD51, two novel mitochondrial binding partners for 6	
dynamin related protein 1 (Drp1), in PAH. 7	
¥ Pathological elevation of MiDs in pulmonary artery smooth muscle cells (PASMC) and 8	
endothelial cells, in human and experimental PAH, accelerates mitotic fission and supports rapid 9	
cell proliferation. 10	
¥ MiD expression is epigenetically upregulated by decreased expression of microRNA-34a-3p. 11	
¥ MiDs cause fission in a Drp1-dependent manner. Silencing MiDs in PAH increases mitochondrial 12	
fusion; conversely, overexpressing MiDs in normal cells causes fission.  13	
¥ Silencing MiDs causes cell cycle arrest (through an ERK1/2 and CDK4-dependent mechanism), 14	
decreases cell proliferation rate and increases apoptosis. 15	
 16	
Clinical Implications: Word count: 100 17	
 18	
¥ We identify a decrease of miR-34a-3p expression in the preclinical models of PAH as well as 19	
reduced circulatory miR-34a-3p expression in patient cohorts. miR-34a-3p may be a biomarker of 20	
PAH. 21	
¥ MiDs are similarly dysregulated in PAH blood outgrowth endothelial cells. 22	
¥ We translated our cellular discoveries into two new therapies that regress PAH. In experimental 23	
models, nebulizing miR-34a-3p or siMiDs regresses pulmonary hypertension 24	
¥ The epigenetic acceleration of mitotic fission through the miR-34a-3p-MiD axis promotes PAHÕs 25	
cancer-like deep phenotype and is a novel therapeutic target.  26	
¥ This study further implicates dysregulation of mitochondrial dynamics as a therapeutic target in 27	
human and experimental PAH. 28	
5	
(Word Count 5883) 1	
Introduction  2	
Pulmonary arterial hypertension (PAH) is a vascular disease in which pulmonary vascular obstruction, 3	
due to vasoconstriction, inflammation, fibrosis and a proliferation/apoptosis imbalance, increases right 4	
ventricular afterload leading to fatal right ventricular failure
1
. Excessive cell proliferation and apoptosis 5	
resistance are important features of pulmonary artery smooth muscle cells (PASMC) in both PAH 6	
patients and rodent models of PAH. This Òneoplastic phenotypeÓ of PAH PASMC persists in cell 7	
culture and is promoted by acquired changes in mitochondrial metabolism, including a shift to 8	
uncoupled glycolysis, known as the Warburg phenomenon
2
, and fragmentation of the mitochondrial 9	
network
3
.  10	
 11	
Mitochondria exist in dynamic networks that undergo continuous fission (division) and fusion (union)
4
. 12	
Altered mitochondrial dynamics in PAH result, in part, from excessive mitochondrial fission caused by 13	
increased activation of the fission-mediating GTPase, dynamin related protein 1 (Drp1)
3, 5, 6
.
 
 When 14	
activated, Drp1 moves from the cytosol to the outer mitochondrial membrane (OMM) where it interacts 15	
with its binding partners in a multimerization reaction that culminates in fission
7-9
. Coordination 16	
between mitosis and mitochondrial division ensures equitable distribution of mitochondria between 17	
daughter cells and is mediated, in part, by a shared dependence of both processes on similar kinases, 18	
including cyclin B-CDK1 (reviewed in
4
). Pathologic levels of Drp1 activation in both PAH and non-19	
small cell lung cancer, the prototypic disease in which proliferation is increased and apoptosis 20	
suppressed, cause mitochondrial fragmentation and promote an imbalance of proliferation and apoptosis 21	
in both conditions
10
. Molecular or chemical inhibition of Drp1 regresses both diseases by causing cell 22	
cycle arrest
3, 10
.   23	
 24	
In mammals, four OMM proteins act as Drp1 receptors: fission 1 (Fis1), mitochondrial fission factor 25	
(MFF), mitochondrial dynamics protein of 49 kDa (MiD49) and mitochondrial dynamics protein of 51 26	
6	
kDa (MiD51)
11
.  MiD49 and MiD51 are expressed on the OMM
12
; however, they also exist in the 1	
cytosol, where their role is unknown
13
. Even the role of MiDs as promoter versus inhibitors of fission 2	
remains controversial and their role in human disease is unknown. Overexpression of either MiD49 or 3	
MiD51 increases Drp1 recruitment to the mitochondria
12
. In one report, MiD overexpression caused 4	
fusion
13
, perhaps by acting as bait for Drp1; however, in another study, overexpression enhanced 5	
fission
14
, perhaps by enhancing the compactness and efficiency of the fission apparatus
12
. The 6	
possibility that MiD49 and MiD51 might have a role in disease has not been assessed, although a recent 7	
report identified a single nucleotide polymorphism in MiD49 that was associated with adverse 8	
remodeling of small pulmonary arteries in PAH
15
. Moreover, the role of endogenous MiDs in normal 9	
cell biology or in human disease is largely unknown, with the few studies to date largely relying on 10	
heterologous overexpression of MiDs in cell lines. 11	
 12	
Here, we examine the fundamental role of these newly discovered Drp1 binding partners in regulating 13	
mitochondrial dynamics and the cell cycle in normal PASMC, and describe the pathologic cause and 14	
consequences of their dysregulation in PAH. We report that the expression of both MiD49 and MiD51 15	
is pathologically elevated in PASMC and small pulmonary arteries (PA) from PAH patients, as well as 16	
in two rodent models of disease. Super resolution confocal imaging reveals the formation of a ring-17	
shaped macromolecular fission apparatus, comprised of MiDs and Drp1, at the site of fission. Silencing 18	
MiD expression restores mitochondrial fusion and reverses the pseudo-neoplastic phenotype of PAH 19	
PASMC by decreasing cell proliferation and increasing apoptosis in human and experimental PAH. The 20	
impact of MiD knockdown on proliferation results as a consequence of cell cycle arrest in G1 phase, 21	
suggesting that mitotic fission is controlled by a cell cycle checkpoint. Furthermore, the progression of 22	
PAH has been linked to the dysregulation of several miRs, including miR-204
16
, miR-126
17
, miR-124
18
, 23	
miR-25
19
 and miR-138
19
. These miRs influence disease processes in a variety of tissues, including the 24	
right ventricle, skeletal muscle and pulmonary vasculature, respectively. In our study we demonstrate 25	
that MiD expression is epigenetically upregulated by a decrease in microRNA (miR)-34a-3p, in both 26	
7	
PAH patients and animal models. Overexpression of either MiD recapitulates the PAH phenotype in 1	
normal PASMC. In contrast, silencing MiD49 or MiD51 or augmenting a miR-34a-3p mimic, reverses 2	
established PAH in vivo, highlighting the contribution of the miR-34a-3p-MiD-Drp1 axis to the 3	
pathophysiology of human and experimental PAH and the viability of this pathway as a target for new 4	
therapeutic strategies.  5	
 6	
Methods 7	
The data, analytic methods will be made available to other researchers for purposes of reproducing the 8	
results or replicating the procedure. But we cannot make the materials available due to their scarcity (in 9	
the case of cells and tissues) or the cost (in case of therapeutic siRNAs and miRs). 10	
Cell culture and reagents: 11	
PAH PASMC were isolated from PAH patients. Normal PASMC were isolated from control subjects or 12	
purchased from Lonza or Cell Applications Inc. PASMC lines were studied within 6 passages. PASMC 13	
were grown in Medium 231 supplemented with Smooth Muscle Growth Supplement (SMGS, Life 14	
Technologies, Carlsbad, CA, USA). Experiments were performed on 6 normal PASMC lines (50% 15	
Female, Mean age: 50.7 years) and 8 PAH PASMC lines (28% Female, Mean age: 41.2 years). Blood 16	
Outgrowth Endothelial Cells (BOEC) were isolated and cultured from PAH patients and normal 17	
individuals (Demographics in Supplementary Table 1) as previously described
20
. Briefly blood was 18	
collected from normal individuals (n=5) and PAH patients (n=6) by venipuncture. Peripheral 19	
blood mononuclear cell (PBMC) was isolated from the whole blood by density gradient 20	
centrifugation. PBMC were cultured in BOEC generation medium for 7-14 days for the 21	
appearance of outgrowth colonies. 22	
Immunohistochemistry: 23	
To assess localization and expression of MiDs in human (normal, n=6, PAH, n=6, Supplementary Table 24	
1) and rodent models (MCT model: Ctrl n=5, MCT n=5; Su/Hx model: Ctrl n=3, Hx n=3, Su/Hx n=3), 25	
8	
lung immunohistochemistry was performed with a Ventana Autostainer (Ventana Discovery XT, 1	
Ventana Medical Systems, Tucson, AZ, USA) using the companyÕs buffer solution and staining 2	
protocol. 3	
Immunofluorescence staining: 4	
Immunofluorescence staining of the formalin-fixed paraffin embedded rat lung tissues was performed as 5	
previously described
21
. Briefly, rat lung sections were labeled with smooth muscle actin (SMA, Abcam, 6	
Cambridge MA, USA), von Willebrand factor (vWF, Dako Denmark A/S, Glostrup, Denmark) 7	
antibodies. Nuclei were labeled with DAPI (Life Technologies, Carlsbad, CA, USA). 8	
Small interfering RNA (siRNA) treatment of PASMC: 9	
For siRNA treatment, PAH PASMC were grown to 60-80% confluence and then transfected with 25 10	
picomole of siRNA using the Lipofectamine¨ RNAiMAX Transfection Reagent (Life Technologies, 11	
Carlsbad, CA). The sequences of siRNA duplexes specific for human MiD49, MiD51, Fis1, MFF, rat 12	
MiD49, MiD51 and negative control are available in the supplementary section. The knock down 13	
efficiency was assessed after 48 hours using qRT-PCR (Bio-Rad, Hercules, CA, USA) and 72 hours 14	
using immunoblotting.  15	
Cell cycle analysis: 16	
To assess the effects of MiD expression on cell cycle progression flow cytometry was performed on 17	
cells that were initially synchronized by serum starvation. PAH PASMC were transfected with siRNA 18	
targeting MiD49 or MiD51 versus a ctrl-siRNA for 24h. After siRNA transfection, the cells were serum 19	
starved for 48 hours to synchronize the cells at G1/G0 phase. The cells were then stimulated with 20% 20	
FBS/Medium 231 for 24h. Cells were harvested, suspended in phosphate-buffered saline (PBS), and 21	
fixed with 70% ethanol (v/v) at -20¡C. The fixed cells were washed twice with cold PBS and incubated 22	
with PI/RNase Staining Buffer (BD Biosciences, Franklin Lakes, NJ, USA) at room temperature for 15 23	
minutes. The samples were analyzed through flow cytometry using a fluorescence-activated cell sorter 24	
(Beckman Coulter Inc, Brea, CA, USA).  25	
Cell proliferation assay: 26	
9	
Cell proliferation was quantified using the Click-iT EdU kit according to the manufacturerÕs instructions 1	
(Life Technologies, Carlsbad, CA, USA). Measurements were made 72h following administration of 2	
siRNA or plasmid transfection. 3	
Apoptosis Assay: 4	
Cells were grown in 100 mm dishes and were harvested and counted at 80-90% confluence. 1.5 x10
6
 5	
cells were electroporated (LONZA 4D-Nucleofactor, Rochester, NY, USA) with ctrl-siRNA, siMiD49 6	
or siMiD51 using the inbuilt program, FG113 following manufacturerÕs instructions. The cells were 7	
collected after 72h and stained with the Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit (Life 8	
Technologies, Carlsbad, CA, USA) following the manufacturerÕs instruction. Detection and 9	
quantification of apoptotic cells were obtained by flow cytometry analysis (Beckman Coulter FC500). 10	
Apoptosis was also assessed by measuring the activity of caspase3/7 after transfecting the PAH PASMC 11	
for 48h using the Caspase-Glo 3/7 Assay Kit (Promega, Madison, WI, USA) following manufacturerÕs 12	
instructions.  13	
Quantification of mitochondrial fission: 14	
Cells grown in glass-bottom dishes (MatTek Corporation, Ashland, MA, USA) were transfected with 15	
siRNAs against either MiD49 or MiD51 or ctrl-siRNA. Cells were loaded with the mitochondrial 16	
potentiometric dye, tetramethylrhodamine (TMRM; 20 nM, 20 minutes in culture medium at 37¡C; 17	
Molecular Probes, Eugene, OR, USA) or infected with Adv-mNeon Green for 48h prior to imaging. 18	
Cells were imaged with a Leica SP8 laser scanning confocal microscope using a 1.40NA, 63X oil 19	
immersion objective with × 2 digital zoom (excitation 561 nm, emission > 575 nm for TMRM and 20	
excitation 491nm, emission 505-530 nm for Adv-mNeon Green; Leica Planapo, Wetzlar, Germany). 21	
Acquired images were background subtracted, filtered (median), thresholded, and binarized to identify 22	
individual mitochondria using ImageJ (U.S. National Institutes of Health (NIH), Bethesda, MD, USA). 23	
Continuous mitochondrial structures were counted with ImageJÕs particle counting subroutine and the 24	
number was normalized to the total mitochondrial area to obtain the mitochondrial fragmentation count 25	
(MFC) for each image, a previously validated measure of mitochondrial fragmentation
10
. For every 26	
10	
intervention, 8-25 randomly selected cells were imaged by a blinded microscopist and MFC was 1	
calculated. A lower MFC indicates a more fused mitochondrial network. 2	
Machine learning: 3	
Mitochondrial morphology was further analyzed by a machine-learning based categorization using the 4	
Leica LAS X software. Briefly, every mitochondrion in each cell was divided into three categories 5	
(punctate, intermediate or filamentous) based on their morphology. Fifteen to twenty mitochondria from 6	
each group were manually identified and categorized in order to inform the machine-learning algorithm. 7	
The algorithm is calculated based on the characteristics (area, length and sphericity) of the mitochondria. 8	
Then the algorithm was applied to all the images. The percentage area of each category in each confocal 9	
image was calculated and the distribution of the three categories was compared among groups. 10	
Mitochondrial Networking: 11	
Mitochondrial Networking was determined with mitochondrial targeted, photo-activatable green 12	
fluorescent protein (Mito-PA-GFP) using a metric called the mitochondrial networking factor (MNF). An 13	
increase in MNF indicates higher degree of mitochondrial network fusion
3, 10
.  14	
Whole Cell Micropolarimetry: 15	
PASMC micropolarimetry was performed by Mitochondrial flux measured with Seahorse XFe24 16	
(Seahorse Biosciences, North Billerica, MA, USA) in PAH PASMC after 48h of transfection with 17	
siMiD49 or siMiD51. A detailed methodology is described in the supplementary section. 18	
miRNA microarray: 19	
To identify candidate miRs that are dysregulated in PAH we performed a miR microarray study. Total 20	
RNA from cultured PASMC of 6 PAH patients and 3 healthy subjects was extracted using the mirVana 21	
miRNA isolation kit (Ambion/Life Technologies). RNA quality was assessed by measurement of 22	
absorbance at 260nm and 280nm using a spectrophotometer (cutoff of 1.8-2.2) and by calculation of a 23	
RNA integrity number (RIN) in an Agilent Bioanalyzer (RIN > 6). Microarray experiments were carried 24	
out at the Centre for Applied Genomics at the Hospital for Sick Children (Toronto, Canada). 25	
Differential expression of miRNAs between the PAH and control cohorts was examined using the 26	
11	
Affymetrix GeneChip miRNA 4.0 Array (Affymetrix, Santa Clara, CA, USA). RNA samples were 1	
prepared using the FlashTag Biotin HSR RNA Labeling Kit (Affymetrix) prior to hybridization at 48¼C 2	
for 16-18h. Fluorescent signals were captured using the Affymetrix GeneChip Scanner 3	
3000. Subsequent signal normalization and analysis were performed using the Affymetrix Expression 4	
Console and Transcriptome Analysis Console software, respectively. A pre-specified 2-fold change 5	
threshold and ANOVA P < 0.05 was used as selection criteria for significantly downregulated miRNAs. 6	
All data have been submitted to the NCBI Gene Expression Ombnibus (GEO; Accession number to 7	
follow peer review). 8	
In silico analysis of miRNAs binding to MiD49 and MiD51: 9	
In order to identify which miRNAs can bind to MiD49 and MiD51, in silico analysis using Target Scan 10	
7.0 and miRDB were used. Out of the 25 downregulated miRNAs, we identified miR-34a-3p as the only 11	
predicted regulator of MiD51. Although none of the downregulated miRNAs were predicted to regulate 12	
MiD49, analysis using nucleotide BLAST identified potential miR-34a-3p target sites within the 3Õ-13	
UTR of MiD49 and MiD51. 3Õ-UTR sequences of MiD49 and MiD51 were obtained from the 14	
University of California, Santa Cruz (UCSC) Gene Sorter (http://genome.ucsc.edu/). The nucleotide 15	
sequence of hsa-miR-34a-3p (Accession # MIMAT0004557) was extracted from miRBase Release 21 16	
(http://www.mirbase.org). 17	
miR-binding luciferase reporter assay: 18	
To validate the binding of candidate miRs to the MiD mRNA we performed a binding assay using (3Õ-19	
UTR) of MiD49 or MiD51 and miR-34a-3p. Reporter plasmids containing the untranslated region (3Õ-20	
UTR) of MiD49 or MiD51 were obtained from GeneCopoeia (Rockville, MD). HEK293A cells were 21	
co-transfected with either MiD49 or MiD51 reporter plasmids together with miR-ctrl or miR-34a-3p 22	
using Lipofectamine 3000 and RNAi MAX transfection reagents (Life Technologies, Carlsbad, CA). 23	
Luciferase activity assay was performed as previously described
19
.  24	
Human blood sample: 25	
Studies of circulatory miR expression of PAH patients versus healthy volunteers (HV) was performed at 26	
12	
the University of Sheffield, UK and FuWai Hospital, Beijing, China. The collection of patient blood 1	
samples was coordinated through the Sheffield NIHR Clinical Research Facility. The study was 2	
approved by the Local Research Ethics Committee and The Sheffield Teaching Hospitals Foundation 3	
Trust Observational Cardiovascular Biobank (08/H1308/193 and STH15222), Sheffield, UK as well as 4	
the institutional review board of FuWai Hospital, Beijing, China. Informed consent was obtained from 5	
each subject before enrolment. Within each cohort HV vs PAH patients were matched for age and sex. 6	
 7	
Animal Studies: 8	
All protocols were approved by the QueenÕs University and Laval University Animal Care Committees.  9	
MCT PAH model:  10	
MCT-induced PAH model in rats was created by subcutaneous injection of 60mg/kg of MCT, as 11	
previously described
21
. PAH was allowed to develop for 7 days prior to intervention. Experiments were 12	
performed 3-weeks following MCT injection. Randomization and blinding were included in the study 13	
design for the duration of the protocol including analysis. 14	
SU5416/hypoxia PAH model: 15	
This model was created as previously described
22
. Experiments were performed 3-weeks following 16	
removal from the hypoxic chamber. 17	
siMiD49 or siMiD51 or miR-34a-3p mimic therapy:  18	
Briefly, 1 nmole of siMiD49 or siMiD51 or ctrl-siRNA and 5nmole of miR-34a-3p or miR-control was 19	
administered 1 week post MCT injection to the anesthetized rat by nebulization in 50µl saline using an 20	
aerosol nebulizer (AG-AL7000STD, Kent Scientific, Torrington, Connecticut, USA). siRNAs were 21	
procured from Integrated DNA Technology (Coralville, IA, USA). miR-34a-3p and miR-control were 22	
purchased from Life Technologies. Both the siRNAs against MiDs and the ctrl-siRNA were modified 23	
for a higher stability for in vivo studies. 24	
Hemodynamics:  25	
mPAP, RVSP, CO were measured using closed-chest technique under isofluorane anesthesia (2.5% 26	
13	
enriched O2; 1.5ml/min), as previously described
21
. 1	
 2	
Statistical analysis:  3	
Quantitative data are presented as the mean ± SEM. Intergroup differences were assessed using 4	
Students' t-test (unpaired or paired) or ANOVA as appropriate. A P < 0.05 was considered statistically 5	
significant.  6	
 7	
Results 8	
Increased expression of MiD49 or MiD51 in PAH 9	
MiD49 and MiD51 expression were increased in PASMC (Fig.1A, Supplementary Fig. 1A) and blood 10	
outgrowth endothelial cells (BOECs; Supplementary Fig. 1B, Supplementary Table 1) from PAH 11	
patients. Confocal microscopy of PAH PASMC localized some of this increased expression to the 12	
mitochondria. Stimulated emission depletion (STED) super-resolution microscopy, which has a 13	
resolution 5-times greater than confocal microscopy (50nm), revealed MiDs within the 14	
macromolecular fission apparatus at the constriction point of the mitochondria, adjacent to 15	
Drp1 (Fig. 1B). The ring-shaped macromolecular fission apparatus is found at points of fission in 16	
normal and PAH PASMC mitochondria. In PAH, we observed more MiDs at the focal area of fission 17	
and noted that the fission apparatus appeared ÒtighterÓ (i.e. more dense) than in normal PASMC. 18	
However, endogenous MiDs are also found in the cytosol, as previously observed
13
. 19	
Immunohistochemistry of lungs from PAH patients (Fig. 1C, Supplementary Table 1) and rats with 20	
monocrotaline (MCT) and Sugen5416/Hypoxia (Su/Hx)-induced PAH  (Fig. 1D and Supplementary 21	
Fig.1C) confirmed the increased expression of MiD49 and MiD51 in the media (PASMC) and intima 22	
(pulmonary artery endothelial cells) of diseased pulmonary arterioles.  23	
 24	
Silencing MiD49 or MiD51 promotes mitochondrial fusion  25	
14	
As reported previously
3
, PAH PASMC exhibits a fragmented mitochondrial network, which was also 1	
observed in PAH BOECs (Supplementary Fig. 1D-E). Resonant scanning showed that effective 2	
knockdown of either MiD (Supplementary Fig. 2A-B) led to increased mitochondrial motion 3	
(Supplementary movies 1-3). Knocking down MiDs also inhibited mitochondrial fission (Fig. 2A) 4	
(reduced mitochondrial fragmentation count, MFC)
10
 and increased percentage area of filamentous 5	
mitochondria (measured by machine-learning) (Fig. 2B). Furthermore, silencing MiDs increased 6	
mitochondrial fusion, evident as an increase in the mitochondrial networking factor (MNF). Increased 7	
MNF reflects a more rapid diffusion of photoactivated GFP within the mitochondrial matrix (Fig. 2C-8	
D). Overexpression of either MiD in PASMC from control subjects led to mitochondrial fission, 9	
creating a phenotype similar to that seen in PAH PASMC (Fig. 2E-F). However, MiD overexpression 10	
failed to cause mitochondrial fragmentation in Drp1 knockout (KO) mouse embryonic fibroblasts 11	
(MEFs; Supplementary Fig. 3A-B), indicating that Drp1 is required for MiD-mediated fission. 12	
Interestingly no significant alteration in the expressions of fusion mediators Mfn1, Mfn2 and OPA1 was 13	
observed by silencing MiD49 in PAH PASMC. Silencing MiD51 reduced the expression of the fusion-14	
mediators, Mfn1 and OPA1 (Supplementary Fig. 4A-C).  15	
 16	
MiDs regulate proliferation, cell cycle progression, apoptosis and oxidative mitochondrial 17	
respiration 18	
Knocking down MiD49 or MiD51 significantly decreased cell proliferation in PASMC from both PAH 19	
patients (Fig. 2G) and control subjects (Supplementary Fig. 5), without altering the expression of other 20	
Drp1 binding partners (Supplementary Fig. 6A). Of note, silencing other Drp1 receptors (MFF and Fis1) 21	
(Supplementary Fig. 6B-C) failed to inhibit cell proliferation (Supplementary Fig. 6D-E) or alter 22	
mitochondrial morphology (Supplementary Fig. 6F-H). In contrast, overexpression of MiD49 or MiD51 23	
in control human PASMC increased cell proliferation (Fig. 2H). Reduced proliferation in response to 24	
siRNA mediated knockdown of MiD49 or MiD51 was accompanied by G1/G0 cell cycle arrest (Fig. 25	
2I). In agreement with these findings, MiD knockdown in PAH PASMC resulted in increased basal 26	
15	
apoptosis rates (Fig. 2J), which were accompanied by increased expression of the apoptotic mediator, 1	
Bak, and decreased phosphorylation of the cell survival-prompting kinase, Akt (Supplementary Fig. 2	
7A). In addition, silencing MiD49 (but not MiD51) increased baseline oxygen consumption in PAH 3	
PASMC (Supplementary Fig. 7B) and upregulated the mitochondrial calcium uniporter (MCU), 4	
consistent with reversal of the Warburg effect. 5	
 6	
Similar to human PAH PASMC, PASMC isolated from MCT PAH and Su/Hx PAH rats retain their 7	
hyperproliferative phenotype in culture and have a fragmented mitochondrial network (Supplementary 8	
Fig. 8A-C). siRNA mediated knockdown of MiD49 decreased cell proliferation in normal rat PASMC, 9	
MCT PAH PASMC and Su/Hx PAH PASMC. However, in the siMiD51 treatment group, despite 10	
induction of fusion, inhibition of cell proliferation was observed in normal rat PASMC and MCT PAH 11	
PASMC but not the Su/Hx PAH PASMC (Supplementary Fig. 8D-G). Consistent with the findings in 12	
human PAH PASMC, siMiDs inhibited mitochondria fission in both MCT and Su/Hx PASMC 13	
(Supplementary Fig. 8H-K). 14	
Silencing MiDs inhibits cell proliferation and mitochondrial fission by inhibiting CDK4 and 15	
PDGF-ERK1/2 signaling  16	
We next investigated the mechanistic pathway that connects MiDs with cell proliferation and 17	
mitochondrial fission in PASMC from human and experimental PAH. Extracellular-signal-regulated 18	
kinases (ERK) promotes phosphorylation of Drp1 at serine 616 (ser616)
23, 24
 and increases cell 19	
proliferation
25
. Knockdown of MiD49 or MiD51 in PAH PASMC reduced the Drp1 ser616 20	
phosphorylation (Fig. 3A, Supplementary Fig. 9A) and decreased ERK1/2 phosphorylation in PAH 21	
PASMC stimulated with platelet derived growth factor (PDGF; Fig. 3B, Supplementary Fig. 9B). 22	
Moreover, silencing MiDs downregulated the expression of the PDGF receptors α and β (Fig. 3C) and 23	
inhibited Raf-1 phosphorylation (Supplementary Fig. 9C) suggesting that silencing MiDs inhibit 24	
mitochondrial fission and cell proliferation, in part, by inhibition of the PDGF-Raf-1-ERK1/2 signaling 25	
pathway.  26	
16	
 1	
Silencing MiDs repressed the expression and activity of cyclin dependent kinase 4 (CDK4) by inhibiting 2	
its phosphorylation at threonine 172 (Thr172)  (Fig. 3D, Supplementary Fig. 9D-E). Furthermore, 3	
silencing MiDs increased expression of the CDK4 inhibitors p21
Waf1
 and p27
Kip1 
(Fig. 3E-F, 4	
Supplementary Fig. 9F). These results suggest that silencing of MiDs cause G1 phase arrest by the 5	
inhibition of CDK4 activity. Conversely, silencing of MiD49 or MiD51 failed to impair the activity of 6	
CDK2, the mediator of G1-S phase transition (Supplementary Fig. 9G).  7	
 8	
Downregulation of miR-34a-3p mediates MiD49 and MiD51 upregulation in PAH   9	
A comparison of miRNA expression profiles in PASMC from PAH patients and normal controls (Fig. 10	
4A) identified 25 miRNAs that were significantly downregulated in PAH (Supplementary Table 2). In 11	
silico analysis of these miRNAs identified potential miR-34a-3p target sites within the 3Õ-UTR of 12	
MiD49 and MiD51 (Fig. 4B). Decreased expression of miR-34a-3p in PAH PASMC was confirmed by 13	
qRT-PCR (Fig. 4C). Binding of miR-34a-3p to the 3Õ-UTR of MiD49 and MiD51 was confirmed using 14	
a luciferase reporter fused to the 3Õ-UTR of the MiD49 or MiD51 gene (Fig. 4D). Co-transfection of 15	
HEK293A cells with miR-34a-3p mimic and the reporter constructs decreased luciferase activity, 16	
confirming binding of the miR to the 3Õ-UTR of MiD49 or MiD51. Downregulation of miR-34a-3p was 17	
also found in the whole blood of MCT and Su/Hx PAH rats (Supplementary Fig. 10A). Two temporally 18	
and geographically discrete cohorts of different ethnicity showed significant decrease in miR-34a-3p 19	
expression in whole blood and plasma from IPAH patients compared to the age- and sex-matched 20	
healthy volunteers (Fig. 4E, Supplementary Table 2). The downregulation of plasma miR-34a-3p 21	
identified patients with PAH (Fig. 4F) but did not predict disease-related mortality (data not shown). 22	
Similar findings were noted in the blood of both preclinical PAH models (Supplementary Fig. 10A). 23	
 24	
Moreover, miR-34a-3p transfection decreased the expression of MiD49 and MiD51 in human PAH 25	
PASMC (Fig. 5A). Conversely, administration of anti-miR-34a-3p increased the expression of MiD49 26	
17	
and MiD51 in both normal human and rat PASMC (Fig. 5B and Supplementary Fig. 10B). Augmenting 1	
miR-34a-3p fused the mitochondrial network, inhibited proliferation, and induced apoptosis in human 2	
PAH PASMC (Fig. 5C-H). miR-34a-3p mimic transfection also decreased proliferation and 3	
mitochondrial fission in PASMC from normal, MCT-PAH and Su/Hx PAH rats. (Supplementary Fig. 4	
10C-G).   5	
 6	
Therapeutic implications of the miR-34a-3p-MiD pathway in vivo 7	
The therapeutic efficacy of silencing MiDs or augmenting miR-34a-3p was determined by nebulizing 8	
rats early in the course of MCT-induced PAH with siRNAs against either MiDs or a miR-34a-3p mimic. 9	
Treatment with either siMiD or the miR-34a-3p mimic, but not appropriate control materials, caused 10	
marked hemodynamic improvement, with decreased mean pulmonary artery pressure (mPAP), right 11	
ventricular systolic pressure (RVSP) and total pulmonary resistance (TPR), as well as increased cardiac 12	
output (CO) (Fig. 6A-B). These hemodynamic benefits were accompanied by regression of vascular 13	
obstruction, as quantified by a decrease in medial thickness in small pulmonary arteries of MCT treated 14	
rats (Fig. 6C, Supplementary Fig. 11A-B). siMiDs (Supplementary Fig. 11C-F) or miR-34a-3p 15	
(Supplementary Fig.11G-J) administration caused no renal or hepatic toxicity.  16	
 17	
 18	
Discussion 19	
This study has 5 novel findings: 1) MiDs cause fission and this is increased in a human disease (PAH). 20	
2) Inhibiting MiD expression prevents mitotic fission in health and disease. 3) MiD inhibition stops cell 21	
proliferation and increases apoptosis. 4) MiD expression is epigenetically upregulated by a decrease in 22	
miR-34a-3p, both in experimental PAH and in PAH patients. 5) These discoveries were translated into 23	
two new therapies that attenuate PAH in a rodent model (nebulized siMiD49 or siMiD51 or nebulized 24	
miR-34a-3p).  25	
 26	
18	
This study clarifies the role of the Drp1 binding partners, MiD49 and MiD51, in normal cell biology, 1	
while simultaneously highlighting the impact of their upregulation on the pathogenesis of PAH. In 2	
normal vascular cells, MiDs function as an important link between mitosis and mitochondrial fission. In 3	
PAH, the upregulation of MiD49 and MiD51 supports increased mitotic mitochondrial fission leading to 4	
pathological mitochondrial fragmentation, cellular proliferation and apoptosis resistance. We were able 5	
to use super resolution microcopy to image, for the first time, the macromolecular fission apparatus 6	
(Fig. 1B). We demonstrated that it contained both Drp1 and MiDs. In PAH there were qualitatively 7	
more MiDs at the site of fission and the fission apparatus appeared denser, consistent with the notion 8	
that increased MiDs focuses the constriction apparatus, thereby enhancing fission
12
. 9	
 10	
Intriguingly, PAH patients displayed individual variation in terms of which of the MiDs was elevated 11	
(Fig. 1A), with patients often exhibiting increased MiD49 or MiD51 relative to control, but not both. 12	
This heterogeneity of expression was also seen at the mRNA level (data not shown). Despite this 13	
heterogeneity, PAH patients displayed a conserved, fragmented mitochondrial phenotype regardless 14	
which of the MiDs was upregulated (Fig. 2A). Overexpression of either MiD49 or MiD51 in isolation 15	
was also sufficient to reproduce the mitochondrial and proliferative phenotype of PAH in normal 16	
PASMC (Fig. 2E-F, 2H), highlighting a redundancy in the function of the two MiDs and suggesting that 17	
even healthy cells possess a sufficient basal pool of activated Drp1 to drive fission and proliferation 18	
when MiD levels increase. Our findings are at odds with Palmer et al. who suggested MiD 19	
overexpression inhibited fission, possibly by sequestering inactivated Drp1
14
. The basis for this 20	
difference is unclear; however, our findings are robust (Fig. 2E-F). 21	
 22	
This work advances the field from an earlier view that fission primarily reflects the expression, activity or 23	
posttranslational modification of Drp1 (reviewed in
4
). It is now clear the expression and function of the 24	
MiDs are critical determinants of mitochondrial dynamics and cell cycle regulation. This view is further 25	
supported by our observation that silencing MiDs is sufficient to restore mitochondrial fusion (Fig. 2A-26	
19	
D), slow cell proliferation (Fig. 2G) and enhance apoptosis (Fig. 2J) in PAH PASMC. In this regard, 1	
MiD49 and MiD51 are unique, since silencing other Drp1 receptor proteins, MFF or Fis1, did not alter 2	
cell proliferation or mitochondrial fission (Supplementary Fig. 6D-H). MiDs appear to have a special role 3	
in the fission that accompanies mitosis whereas Fis1 appears to be important in pathologic fission, as 4	
occurs in ischemia-reperfusion injury
26
. While MiDs regulate fission independently of other Drp1 binding 5	
partners (Supplementary Fig. 6A), the inability of MiDs to promote fission in MEFs lacking Drp1 6	
(Supplementary Fig. 3) demonstrates that the availability of activated Drp1 is essential to this process. 7	
This new work adds detail to our previous discovery that inhibiting mitotic fission slows cell cycle 8	
progression. We are now showing the Drp1 binds MiDs to mediate mitotic fission. Super-resolution 9	
microscopy demonstrates the assembly of these partners at focal areas of fission, as part of the 10	
macromolecular fission apparatus (Fig. 1B). The Drp1-dependent proliferative effect of MiDs indicates 11	
that they are obligatory Drp1 binding partners in hyperproliferative disease. We did not study the effects 12	
of MiD expression on mitochondrial membrane potential. 13	
 14	
Besides hyperproliferation and apoptosis resistance, PAH PASMC exhibit another pseudo-neoplastic 15	
phenotype by displaying perturbed oxygen sensing due to dysregulated mitochondrial redox signaling. 16	
This increases reliance on glycolysis thereby creating WarburgÕs phenomenon
2
.  We show that inhibiting 17	
MiDs increases apoptosis (Fig. 2J) and restores oxidative metabolism and MCU expression 18	
(Supplementary Fig. 7B-C), consistent with our recent discovery that the downregulation of MCU is a 19	
central contributor to both Warburg metabolism and fission in PAH
19
 (Supplementary Fig. 7B). This 20	
indicates that the miR-34a-3p-MiD-Drp1 pathway interacts with the miR-25- and -138-MCU pathway. 21	
 22	
We also identified the mechanisms by which MiDs regulate fission and cell cycle progression (Fig. 7A). 23	
MiDs are Drp1 binding partners and attract more Drp1 to the OMM
12
. Thus, greater MiD expression is 24	
expected to enhance fission, as observed (Fig. 2E-F). However, we show that MiDs also regulate 25	
kinases that control Drp1 activity. Drp1 phosphorylation can be initiated by several kinases, including 26	
20	
CDK1 and ERK
10, 23, 24
, which activate Drp1 through phosphorylation of serine 616
3, 27
. We found that 1	
silencing MiDs inhibited ERK1/2 (Fig. 3B) and decreased phosphorylation of Drp1 at serine 616 (Fig. 2	
3A), supporting the dual mechanisms of MiD-induced fission. However silencing MiDs did not increase 3	
the expression of the mitochondrial fusion mediators Mfn1, Mfn2 and OPA1. Indeed, siMiD51 4	
decreased the expression of Mfn1 and OPA1 (Supplementary Fig. 4A-C). Thus siMiD-mediated 5	
mitochondrial fusion does not result from upregulation of fusion mediators. 6	
 7	
Knocking down MiDs caused cell cycle arrest at G1/G0 phase (Fig. 2I). Progression of cell cycle in 8	
early G1 phase versus the transition from G1-S phase is mediated by CDK4 versus CDK2, 9	
respectively
28
. The activation of CDK2 involves dephosphorylation of Tyr15 and Thr14
29
. Our results 10	
revealed that silencing MiDs does not inhibit CDK2 activity, as evidenced by the unchanged 11	
phosphorylation status at Tyr15 of CDK2 (Supplementary Fig. 9G).
 
 However, knocking down MiDs 12	
inhibited CDK4 activity by downregulating CDK4 expression and phosphorylation at Thr172
30
 (Fig. 13	
3D, Supplementary Fig. 9D-E). Silencing MiDs also increased the expression of the CDK4 inhibitor 14	
p21
Waf1 31 
and p27
Kip132 
(Fig. 3E-F and Supplementary Fig. 9F). Our observation is supported by studies 15	
showing that ERK is a negative regulator of p27
Kip133, 34
. Therefore siMiDs mediated inhibition of cell 16	
cycle arrest can be explained by the inhibition of ERK1/2 activity achieved by silencing MiDs which in 17	
turn activates p27
Kip1 
resulting in decreased CDK4 activity. When taken together, these results show a 18	
multifactorial mechanism underlying the inhibition of mitochondrial fission and cell cycle arrest at G1 19	
phase achieved by silencing MiDs (Figs. 2A-D, 2I, 7A). We previously showed that inhibiting Drp1 or 20	
augmenting Mfn2, both resulting in impaired mitotic fission, also results in cell cycle arrest
10
. 21	
 22	
In addition to these effects on cell cycle kinases, silencing MiDs also downregulated PDGF receptors α 23	
and β (Fig. 3C). PDGF is a potent mitogen, which triggers cell proliferation, migration, transformation 24	
and survival 
35-37
, all processes relevant to the pathogenesis of PAH. Indeed, PDGF receptors are 25	
activated in PAH
38
 and inhibitors of PDGF receptor, such as Imatinib, have demonstrated therapeutic 26	
21	
benefit in animal models and in some patients
38, 39
. PDGF binding to the PDGF receptors activates the 1	
MAPK signal transduction cascade resulting in the phosphorylation and activation of ERK1/2. 2	
Activated ERK1/2 then translocates to the nucleus and enhances the expression of transcription factors 3	
related to cell proliferation
40
.  It is likely that siMiD-induced downregulation of PDGF receptors 4	
contributes to the observed inhibition of cell proliferation via the MAPK signaling pathway as 5	
evidenced by the inhibition of the two members of the MAPK signaling pathway, Raf-1 and ERK1/2 6	
(Fig. 3B-C, Supplementary Fig. 9B-C)  (see proposed pathway schematic Fig. 7A). Although interaction 7	
between MiDs and PDGF receptors remains speculative, it is important to note that MiDs are located on 8	
the outer mitochondrial membrane and they possess free cytosolic domains responsible for Drp1 9	
binding
13, 14
. Furthermore, mitochondria are highly motile, dynamic organelles. Indeed the outer 10	
mitochondrial membrane protein Mfn2 interacts with Ras, which is also located on cell membrane, just 11	
like PDGF receptors
41, 42
. Therefore, it is not unlikely that MiDs may directly interact with PDGF 12	
receptors. 13	
 14	
The current study identifies depressed miR-34a-3p expression as the primary driver of pathologic MiD 15	
upregulation in PAH. In general, upregulation of a miR suppresses its target species whilst 16	
downregulation of the miR, as in the case of miR-34a-3p in PAH PASMC, would be expected to permit 17	
increase expression of its targets (MiD49 and MiD51). The ability to increase (Fig.5B, Supplementary 18	
Fig. 10B) or decrease (Fig. 5A) MiDs through manipulation of miR-34a-3p confirms the central role 19	
that this miR plays in the mitochondrial fission phenotype of PAH. Further certainty of the predicted 20	
role of miR-34a-3p in regulating MiDs comes from our direct experimental confirmation that the miR 21	
indeed binds and inhibits the 3Õ-UTR of both MiD49 and MiD51 (Fig. 4F). 22	
 23	
Although the role of miR-34a-3p is not well established in human disease, its complementary strand, 24	
miR-34a-5p, has been implicated in many human cancers
43-45
 and in PAH, where its suppression has 25	
been linked to the PDGF receptor α-mediated hyperproliferation of human PASMCs
46
 and vascular 26	
22	
remodeling in response to chronic hypoxia
47
. Additional reports have shown that miR-34-3p is co-1	
expressed with its complementary 5p strand in cancer cells; however, it targets different groups of 2	
transcripts
48
. Intriguingly, the downregulation of miR-34a-3p expression in PAH may relate to the 3	
hypermethylation of the CpG island in the promoter region of the MIR34A gene. This is supported by 4	
the studies with several cancers which displayed CpG methylation of the promoter of the precursor 5	
MIR34A and subsequent loss of miR-34a-5p expression
49, 50
. 6	
 7	
Here, we demonstrate a consistent downregulation of miR-34a-3p in three PAH patient cohorts and two 8	
rodent models of PAH (Supplementary Fig. 10A). Decreased miR-34a-3p expression was observed in 9	
PASMC from Canadian subjects (Fig. 4C) as well as in the whole blood and plasma collected from UK 10	
and China cohorts (Fig. 4D). Because circulating levels of miR-34-3p are depressed in PAH patients, 11	
which correlates with expression in the PASMC itself, this miR also has potential as a diagnostic test for 12	
PAH. The expression of circulatory miR-34a-3p predicted the presence of PAH but did not predict 13	
clinical outcomes (Fig. 4E), suggesting that larger sample sizes may be required to confirm the 14	
usefulness of this miR as a biomarker for PAH. 15	
 16	
Our in vitro data, demonstrate that inhibition of MiDs causes a sustained state of mitochondrial fusion 17	
(Fig. 2A-D), which decreases PASMC proliferation (Fig. 2G and Supplementary Figs. 5, 8E-G) and 18	
promotes apoptosis (Fig. 2J). These findings provide the biologic plausibility for the therapeutic 19	
targeting of MiDs or augmenting miR-34a-3p in PAH. We confirmed these therapeutic benefits by 20	
nebulizing siMiDs and miR-34a-3p in vivo and demonstrating the ability of these approaches to regress 21	
experimental PAH and reduce cell proliferation in vivo (Fig. 6A-C). These findings are consistent with 22	
our previous observations that creating a state of sustained mitochondrial fusion, whether by inhibiting 23	
Drp1
3
 or augmenting the fusion mediator, mitofusin-2
22
, arrests cell proliferation and regresses PAH. 24	
 25	
Limitations: There are few reports of the function or localization of MiD49 and 51. It has been reported 26	
23	
that both MiDs are exclusively located at the outer mitochondrial membrane
51
. This study relied on 1	
heterologous overexpression of MiDs. However, we noted that MiDs are also expressed in the cytosol. 2	
This is consistent with a prior report, which noted that while MiD51 was predominantly a mitochondrial 3	
protein, it also existed in the cytosol
13
. Extra-mitochondrial MiD may reflect the balance between levels 4	
of MiD and activated Drp1 or the existence of a splice variant/isoform of MiDs that targets the MiD to 5	
an extra mitochondrial location. Perhaps, like Drp1 itself, the MiDs may be involved in the division of 6	
other organelles, such as lysosomes. These questions merit future study. 7	
 8	
In conclusion, excessive mitochondrial fission, which results in mitochondrial fragmentation, is a new 9	
hallmark of proliferative diseases, including PAH and cancer
3, 10
. We have shown that expression of the 10	
Drp1 binding partners, MiD49 and MiD51, are increased in PAH and that this increase drives 11	
pathological mitochondrial fission, cell proliferation and apoptosis resistance. To our knowledge, this is 12	
the first description of a role for dysregulated expression of MiD49 and MiD51 in human disease and 13	
clarifies the role of these Drp1 binding partners in normal cell biology. We also report increased MiD49 14	
and MiD51 expression in the endothelium of diseased pulmonary arteries, as well as in BOECs isolated 15	
from PAH patients (Fig. 1C and Supplementary Fig. 1B). Although the role of MiDs in the endothelium 16	
was not examined in detail in the current study, the mitochondria in PAH BOECs are also fragmented 17	
(Supplementary Fig. 1D-E), indicating that similar mechanisms may be driving altered cellular 18	
proliferation and apoptosis-resistance in this compartment of the vascular wall. Our work identifies 19	
decreased expression of miR-34a-3p as the cause of upregulated MiD49 and MiD51 in human PAH and 20	
highlights the potential value of this miR, as a novel biomarker. Together, these studies identify the 21	
miR-34-3p-MiD-Drp1 axis as an important driver of the mitochondrial and cellular phenotype of PAH 22	
and a new target for therapeutic intervention. A schematic representation of the proposed role of miR-23	
34a-3p in regulating MiD49 and MiD51 in PAH is provided in Fig. 7B.  24	
 25	
   26	
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Figure Legends 1	
Fig. 1: Pathological upregulation of MiD49 and MiD51 in human and experimental PAH. 2	
(A) Representative immunoblots and densitometry demonstrating increased protein expression of 3	
MiD49 and MiD51 in human PAH PASMC (n=6) vs normal human PASMC (n=3). β-actin was used 4	
as the loading control (*P < 0.05). 5	
(B) Confocal images showing higher expression of MiD49 and MiD51 in PAH PASMC. STED 6	
super-resolution images showing association of MiDs with mitochondria and Drp1. Staining used in 7	
the images to create colors: mitochondria (red, MitoTracker
TM
 Deep Red), MiD49, MiD51 (green) and 8	
Drp1 (cyan) in normal and PAH PASMC. Scale bar: 10 µm for the confocal images and 1 µm for the 9	
STED images.  10	
(C) Representative images and quantification of immunohistochemistry demonstrating increased 11	
expression of MiD49 and MiD51 protein (brown) in the media and intima of small pulmonary 12	
arteries from human PAH lungs vs control lungs. 11-14 distal pulmonary arteries, <200µm in diameter 13	
from 6 subjects per group (***P < 0.001; n=11-14/subject). Scale bar: 25 µm. 14	
(D) Representative images and quantification of immunohistochemistry demonstrating increased 15	
expression of MiD49 and MiD51 (brown) in the media and intima of distal pulmonary arteries from 16	
MCT PAH rats. 8-14 distal pulmonary arteries (<150 µm) from 5 animals per group  (***P < 0.001). 17	
Scale bar: 25 µm. 18	
Fig. 2: MiD49 or MiD51 regulates mitochondrial network, cell proliferation and apoptosis. 19	
(A) Mitochondrial fragmentation in PAH PASMC is reversed by silencing of MiD49 or MiD51. 20	
Representative images of mitochondrial networks of normal PASMC and PAH PASMC stained with the 21	
potentiometric dye TMRM (red). PAH PASMC were transfected with the specified siRNA, infected with 22	
Adv-mNeon Green and imaged after 48h following infection. Mitochondria were color coded by their 23	
morphology: green: punctate; red: intermediate; purple: filamentous. Scale bar: 10µm. 24	
30	
(B) Silencing of MiD49 or MiD51 reduces mitochondrial fission. Mitochondrial fragmentation was 1	
quantified by mitochondrial fragmentation count (MFC) and percentage area of punctate, intermediate 2	
and filamentous mitochondria of each image (***P < 0.001; n=15/group).  3	
(C) Mitochondrial network is restored in PAH PASMC by silencing of MiD49 or MiD51. 4	
Representative images of the photoactivation experiments confirmed the increase in mitochondrial 5	
network in PAH PASMCs co-transfected with specified siRNA and mitochondrial matrix targeted green 6	
fluorescent protein (mito-PAGFP) for 48 h. The cells were also loaded with TMRM (red). Scale bar: 7	
10µm. 8	
(D) Silencing of MiD49 or MiD51 increases mitochondrial networking factor (MNF). Mitochondrial 9	
network is quantified by determining mitochondrial networking factor (MNF) which is increased in PAH 10	
PASMC following silencing of MiD49 or MiD51 (*P < 0.05, **P < 0.01; n=5/group; AU: Arbitrary 11	
unit). 12	
(E) Augmenting MiD49 or MiD51 in normal human PASMC induces mitochondrial fission. 13	
Representative images of mitochondrial networks of normal human PASMC transfected with the 14	
specified plasmid. Cells were loaded with TMRM (red). Scale bar: 10µm. 15	
(F) Augmentation of MiD49 or MiD51 significantly increases mitochondrial fragmentation (*P < 16	
0.05, ***P < 0.001; n=15/group).  17	
(G) Proliferation of PAH PASMC is inhibited by silencing MiD49 or MiD51. Cell proliferation was 18	
analyzed 72h post-transfection (*P < 0.05, **P < 0.01; n=3/group). 19	
(H) Proliferation of normal PASMC is increased by overexpressing MiD49 or MiD51. Cell 20	
proliferation was analyzed 72h post-transfection (*P < 0.05, **P < 0.01; n=3/group). 21	
(I) Silencing of MiD49 or MiD51 induces cell cycle arrest in the G1/G0 phase. PAH PASMC was 22	
transfected with siMiD49 or siMiD51 for 24h, serum starved for 48h, and then serum stimulated for 24h. 23	
Cell cycle analyses were performed by flow cytometry following propidium iodide (PI) staining (**P < 24	
0.01; n=3/group). 25	
31	
(J) Silencing of MiD49 or MiD51 increases baseline apoptosis. PAH PASMCs were labeled with 1	
Annexin V
FITC
 and PI and assessed by flow cytometry analyses 72h post-transfection (*P < 0.05, **P < 2	
0.01; n=3/group). 3	
 Fig. 3: Silencing MiDs modulates molecular mediators that promote Drp1-induced mitochondrial 4	
fission and cell proliferation. 5	
(A-F) Silencing MiD49 or MiD51 inhibits phosphorylation of Drp1
Ser616
 and reduces activation of 6	
ERK1/2 and CDK4 while reducing expression of PDGF receptors. Representative images of the 7	
immunoblots and the densitometry of the expressions of (A) p-Drp1
ser616
, (B) p-ERK1/2, (C) PDGF 8	
receptors, α and β, (D) p-CDK4
Thr172
, (E) p21
Waf1
 and (F) p27
Kip1
. PAH PASMCs were transfected with 9	
siMiD49 or siMiD51. Cells were harvested for immunoblot analyses after 48h of transfection. β-actin was 10	
used as the loading control (*P < 0.05, **P < 0.01, ***P < 0.001;  n=3-4/group). 11	
Fig. 4: miR-34a-3p is decreased in PAH and is a negative regulator of MiD49 and MiD51. 12	
(A) miRNA expression profiling in PAH and normal PASMCs. Volcano plot showing expression 13	
change of miRNAs in PAH relative to control samples. Each dot represents one probe set. Red: reduction; 14	
green: increase; n=3 for normal PASMC and n=6 for PAH PASMC. 15	
(B) In silico prediction of miR-34a-3p targeting MiD49 and MiD51. (i) The putative binding site of 16	
miR-34a-3p on the 3Õ-UTR of MiD49 as predicted by nucleotide BLAST. (ii) Nucleotide sequences of 17	
MiD49 3Õ-UTR and miR-34a-3p. The predicted binding site is highlighted in red. Nucleotide positions 18	
are indicated in parentheses. The expect value is calculated by BLAST to describe the number of hits one 19	
can ÒexpectÓ to see by chance. The lower the E-value, the more significant the match. (iii) The two 20	
putative binding sites of miR-34a-3p on the 3Õ-UTR of MiD51. (iv) Nucleotide sequences of MiD51 3Õ-21	
UTR and miR-34a-3p. Predicted target sites are highlighted in blue. 22	
(C) miR-34a-3p is decreased in PAH PASMC. Quantification of miR-34a-3p was performed by qRT-23	
PCR (**P < 0.01; n=4 for normal PASMC and n=6 for PAH PASMC). 24	
32	
(D) miR-34a-3p binds to 3Õ-UTR of MiD49 and MiD51. miR-34a-3p was found to repress the activity 1	
of luciferase reporter, indicating its binding to the 3Õ-UTR of MiD49 and MiD51 gene (**P < 0.01; n=5 2	
and 8 for MiD49 and MiD51 respectively). 3	
(E) miR-34a-3p is decreased in whole blood and plasma from IPAH patients. miR-34a-3p expression 4	
from whole blood and plasma from two cohorts were normalized to U6 and miR-23a-3p respectively, and 5	
analyzed by qRT-PCR  (*P < 0.05, ***P < 0.001; n=11-29 for healthy volunteer and n=14-39 for IPAH 6	
patient). 7	
(F) miR-34a-3p identified patients with IPAH. Receiver operating characteristic (ROC) curves 8	
showing sensitivity and specificity of whole blood and plasma miR-34a-3p for differentiating patients 9	
with IPAH from healthy volunteers at the time of diagnosis (Sheffield whole blood: AUC=0.7857, P = 10	
0.0160; Beijing whole blood: AUC=0.807, P = 0.0002; Sheffield plasma: AUC=0.7573, P = 0.0010; 11	
Beijing plasma: AUC=0.8846, P < 0.0001). 12	
Fig. 5: Increasing expression of miR-34a-3p downregulates MiD49 and MiD51 in PAH PASMC; 13	
administering anti-miR-34a-3p upregulates MiD49 and MiD51 in normal PASMC. 14	
(A) Overexpression of miR-34a-3p downregulates MiD49 and MiD51. Representative images of 15	
immunoblots and densitometry showing the expressions of MiD49 and MiD51 in PAH PASMC 16	
transfected with miR-34a-3p. Cells were transfected with miR-34a-3p for 72h. β-actin was used as the 17	
loading control (*P < 0.05; n=3-4/group). 18	
(B) Anti-miR-34a-3p treatment upregulates MiD49 and MiD51 in normal PASMC. Representative 19	
images of immunoblots and densitometry showing the expressions of MiD49 and MiD51 in normal 20	
human PASMC transfected with anti-miR-34a-3p for 72h. β-actin was used as the loading control (*P < 21	
0.05; n=4/group). 22	
(C-H) Overexpression of miR-34a-3p inhibits mitochondrial fission, cell proliferation and induces 23	
apoptosis in PAH PASMC.  24	
(C) Representative images of mitochondrial networks of PAH PASMC transfected with miR-34a-3p 25	
mimic. The cells were also infected with Adv-mNeon Green and imaged 48h following infection. 26	
33	
Mitochondria were color coded by their morphology: green: punctate; red: intermediate; purple: 1	
filamentous. Scale bar: 10µm.  2	
(D) Mitochondrial fragmentation was quantified by mitochondrial fragmentation count (MFC) and 3	
percentage of area of punctate, intermediate and filamentous mitochondria (***P < 0.01; n=16-4	
20/group).  5	
(E) Mitochondrial network is restored in PAH PASMC by augmenting miR-34a-3p. Representative 6	
images of the photoactivation experiments confirmed the increase in mitochondrial network in PAH 7	
PASMCs co-transfected with miR-34a-3p and mitochondrial matrix targeted green fluorescent protein 8	
(mito-PAGFP) for 48 h. The cells were also loaded with the potentiometric dye TMRM (red). Scale bar: 9	
10µm. 10	
(F) Quantification of mitochondrial network in PAH PASMC by augmenting miR-34a-3p. 11	
Mitochondrial network is quantified by determining mitochondrial networking factor (MNF) which is 12	
increased in PAH PAMC following transfection with miR-34a-3p mimic. (*P < 0.05; n=6/group; AU: 13	
Arbitrary unit). 14	
(G) Augmenting miR-34a-3p inhibits proliferation of PAH PASMC. Cell proliferation was analyzed 15	
72h following miR-34a-3p mimic transfection in PAH PASMC (*P < 0.05; n=3/group). 16	
(H) Augmenting miR-34a-3p induces apoptosis of PAH PASMC. PAH PASMC transfected with miR-17	
34a-3p mimic. Apoptosis was assessed by measuring the activity of caspase3/7 48h following transfection 18	
with miR-34a-3p mimic (n=2 IPAH PASMC lines/group). 19	
Fig. 6. Demonstration of the therapeutic relevance of the miR-34a-3p-MiD pathway in preclinical 20	
model. 21	
(A) Nebulized siMiDs regresses monocrotaline-induced PAH (MCT PAH). Compared to control rats, 22	
MCT PAH rats had elevated PAP, RVSP and decreased CO, as determine by closed-chest right heart 23	
catheterization.  siMiD49 and siMiD51 treatments were effective in decreasing PAP, RVSP and 24	
increasing CO resulting in significant decrease of TPR (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 25	
0.0001; One way ANOVA, n=4-10/group).  26	
34	
(B) Augmenting miR-34a-3p regresses MCT PAH.  Decreased PAP, RVSP and increased CO resulting 1	
in significant decrease of TPR (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; One-way 2	
ANOVA, n=4-10/group).  3	
(C) Representative images of longitudinal and cross sections of small pulmonary arteries and 4	
summary data indicating the regression of PAH caused by siMiD49 or siMiD51 or by miR-34a-3p 5	
mimic was associated with a decrease in the wall thickness in MCT PAH rats. Regression of PAH 6	
was assessed by measuring % of wall thickness by immunofluorescence staining of smooth muscle actin 7	
and von Willebrand Factor (vWF) (***P < 0.001; One-way ANOVA, n=4-5/group).  Scale bar: 50µm. 8	
Fig. 7. Demonstration of the therapeutic relevance of the miR-34a-3p-MiD pathway in preclinical 9	
model. 10	
(A) Representation of the proposed miR-MiDs pathway in PAH relative to normal. (B) Decreased 11	
expression of miR-34a-3p in PAH patients leads to increased expression of the Drp1 binding partners 12	
MiD49 and MiD51 which in turn increases mitotic fission and promotes cell proliferation. 13	
 14	
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Fig.	1:	Pathological	upregula0on	of	MiD49	and	MiD51	in	human	and	experimental	PAH.	
(A)	 Representa0ve	 immunoblots	 and	 densitometry	 demonstra0ng	 increased	 protein	 expression	 of	MiD49	 and	MiD51	 in	 human	 PAH	
PASMC	(n=6)	vs	normal	human	PASMC	(n=3).	β-ac)n	was	used	as	the	loading	control	(*P	<	0.05).	
(B)	Confocal	images	showing	higher	expression	of	MiD49	and	MiD51	in	PAH	PASMC.	STED	super-resolu0on	images	showing	associa0on	
of	MiDs	with	mitochondria	and	Drp1.	Staining	used	in	the	images	to	create	colors:	mitochondria	(red,	MitoTrackerTM	Deep	Red),	MiD49,	
MiD51	(green)	and	Drp1	(cyan)	in	normal	and	PAH	PASMC.	Scale	bar:	10	μm	for	the	confocal	images	and	1	μm	for	the	STED	images.		
(C)	 Representa0ve	 images	 and	 quan0ﬁca0on	 of	 immunohistochemistry	 demonstra0ng	 increased	 expression	 of	 MiD49	 and	 MiD51	
protein	 (brown)	 in	 the	media	and	 in0ma	of	small	pulmonary	arteries	 from	human	PAH	 lungs	vs	control	 lungs.	11-14	distal	pulmonary	
arteries,	<200μm	in	diameter	from	6	subjects	per	group	(***P	<	0.001;	n=11-14/subject).	Scale	bar:	25	μm.	
(D)	 Representa0ve	 images	 and	 quan0ﬁca0on	 of	 immunohistochemistry	 demonstra0ng	 increased	 expression	 of	 MiD49	 and	 MiD51	
(brown)	in	the	media	and	in0ma	of	distal	pulmonary	arteries	from	MCT	PAH	rats.	8-14	distal	pulmonary	arteries	(<150	μm)	from	5	animals	
per	group		(***P	<	0.001).	Scale	bar:	25	μm.	
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Fig.	2:	MiD49	or	MiD51	regulates	mitochondrial	network,	cell	prolifera0on	and	apoptosis.	
(A)	Mitochondrial	 fragmenta0on	 in	 PAH	 PASMC	 is	 reversed	 by	 silencing	 of	MiD49	 or	MiD51.	 Representa)ve	 images	 of	 mitochondrial	
networks	 of	 normal	 PASMC	 and	 PAH	 PASMC	 stained	 with	 the	 poten)ometric	 dye	 TMRM	 (red).	 PAH	 PASMC	were	 transfected	 with	 the	
speciﬁed	 siRNA,	 infected	 with	 Adv-mNeon	 Green	 and	 imaged	 a\er	 48h	 following	 infec)on.	 Mitochondria	 were	 color	 coded	 by	 their	
morphology:	green:	punctate;	red:	intermediate;	purple:	ﬁlamentous.	Scale	bar:	10μm.	
(B)	 Silencing	 of	 MiD49	 or	 MiD51	 reduces	 mitochondrial	 ﬁssion.	 Mitochondrial	 fragmenta)on	 was	 quan)ﬁed	 by	 mitochondrial	
fragmenta)on	 count	 (MFC)	 and	 percentage	 area	 of	 punctate,	 intermediate	 and	 ﬁlamentous	mitochondria	 of	 each	 image	 (***P	 <	 0.001;	
n=15/group).		
(C)	 Mitochondrial	 network	 is	 restored	 in	 PAH	 PASMC	 by	 silencing	 of	 MiD49	 or	 MiD51.	 Representa)ve	 images	 of	 the	 photoac)va)on	
experiments	conﬁrmed	the	increase	in	mitochondrial	network	in	PAH	PASMCs	co-transfected	with	speciﬁed	siRNA	and	mitochondrial	matrix	
targeted	green	ﬂuorescent	protein	(mito-PAGFP)	for	48	h.	The	cells	were	also	loaded	with	TMRM	(red).	Scale	bar:	10μm.	
(D)	 Silencing	of	MiD49	or	MiD51	 increases	mitochondrial	networking	 factor	 (MNF).	Mitochondrial	network	 is	quan)ﬁed	by	determining	
mitochondrial	networking	factor	(MNF)	which	is	increased	in	PAH	PASMC	following	silencing	of	MiD49	or	MiD51	(*P	<	0.05,	**P	<	0.01;	n=5/
group;	AU:	Arbitrary	unit).	
(E)	Augmen0ng	MiD49	or	MiD51	in	normal	human	PASMC	induces	mitochondrial	ﬁssion.	Representa)ve	images	of	mitochondrial	networks	
of	normal	human	PASMC	transfected	with	the	speciﬁed	plasmid.	Cells	were	loaded	with	TMRM	(red).	Scale	bar:	10μm.	
(F)	Augmenta0on	of	MiD49	or	MiD51	signiﬁcantly	increases	mitochondrial	fragmenta0on	(*P	<	0.05,	***P	<	0.001;	n=15/group).		
(G)	Prolifera0on	of	PAH	PASMC	is	inhibited	by	silencing	MiD49	or	MiD51.	Cell	prolifera)on	was	analyzed	72h	post-transfec)on	(*P	<	0.05,	
**P	<	0.01;	n=3/group).	
(H)	Prolifera0on	of	normal	PASMC	is	increased	by	overexpressing	MiD49	or	MiD51.	Cell	prolifera)on	was	analyzed	72h	post-transfec)on	
(*P	<	0.05,	**P	<	0.01;	n=3/group).	
(I)	Silencing	of	MiD49	or	MiD51	induces	cell	cycle	arrest	in	the	G1/G0	phase.	PAH	PASMC	was	transfected	with	siMiD49	or	siMiD51	for	24h,	
serum	starved	for	48h,	and	then	serum	s)mulated	for	24h.	Cell	cycle	analyses	were	performed	by	ﬂow	cytometry	following	propidium	iodide	
(PI)	staining	(**P	<	0.01;	n=3/group).	
(J)	Silencing	of	MiD49	or	MiD51	 increases	baseline	apoptosis.	PAH	PASMCs	were	 labeled	with	Annexin	VFITC	and	PI	and	assessed	by	ﬂow	
cytometry	analyses	72h	post-transfec)on	(*P	<	0.05,	**P	<	0.01;	n=3/group).	
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Fig.	3:	Silencing	MiDs	modulates	molecular	mediators	that	promote	Drp1-induced	mitochondrial	ﬁssion	and	cell	prolifera0on.	
(A-F)	 Silencing	 MiD49	 or	 MiD51	 inhibits	 phosphoryla0on	 of	 Drp1Ser616	 and	 reduces	 ac0va0on	 of	 ERK1/2	 and	 CDK4	 while	 reducing	
expression	of	PDGF	receptors.	Representa)ve	images	of	the	immunoblots	and	the	densitometry	of	the	expressions	of	(A)	p-Drp1Ser616,	(B)	
p-ERK1/2,	 (C)	 PDGF	 receptors,	 α	 and	 β,	 (D)	 p-CDK4Thr172,	 (E)	 p21
Waf1	 and	 (F)	 p27Kip1.	 PAH	 PASMCs	 were	 transfected	 with	 siMiD49	 or	
siMiD51.	Cells	were	harvested	for	immunoblot	analyses	a\er	48h	of	transfec)on.	β-ac)n	was	used	as	the	loading	control	(*P	<	0.05,	**P	<	
0.01,	***P	<	0.001;	n=3-4/group).	
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Fig.	4:	miR-34a-3p	is	decreased	in	PAH	and	is	a	nega0ve	regulator	of	MiD49	and	MiD51.	
(A)	miRNA	expression	proﬁling	in	PAH	and	normal	PASMCs.	Volcano	plot	showing	expression	change	of	miRNAs	in	PAH	rela)ve	to	control	
samples.	Each	dot	represents	one	probe	set.	Red:	reduc)on;	green:	increase;	n=3	for	normal	PASMC	and	n=6	for	PAH	PASMC.	
(B)	 In	silico	predic0on	of	miR-34a-3p	targe0ng	MiD49	and	MiD51.	 (i)	The	puta)ve	binding	site	of	miR-34a-3p	on	the	3’-UTR	of	MiD49	as	
predicted	by	nucleo)de	BLAST.	(ii)	Nucleo)de	sequences	of	MiD49	3’-UTR	and	miR-34a-3p.	The	predicted	binding	site	is	highlighted	in	red.	
Nucleo)de	posi)ons	are	indicated	in	parentheses.	The	expect	value	is	calculated	by	BLAST	to	describe	the	number	of	hits	one	can	“expect”	
to	see	by	chance.	The	lower	the	E-value,	the	more	signiﬁcant	the	match.	(iii)	The	two	puta)ve	binding	sites	of	miR-34a-3p	on	the	3’-UTR	of	
MiD51.	(iv)	Nucleo)de	sequences	of	MiD51	3’-UTR	and	miR-34a-3p.	Predicted	target	sites	are	highlighted	in	blue.	
(C)	miR-34a-3p	is	decreased	in	PAH	PASMC.	Quan)ﬁca)on	of	miR-34a-3p	was	performed	by	qRT-PCR	(**P	<	0.01;	n=4	for	normal	PASMC	
and	n=6	for	PAH	PASMC).	
(D)	miR-34a-3p	binds	 to	3’-UTR	of	MiD49	and	MiD51.	miR-34a-3p	was	 found	 to	 repress	 the	ac)vity	of	 luciferase	 reporter,	 indica)ng	 its	
binding	to	the	3’-UTR	of	MiD49	and	MiD51	gene	(**P	<	0.01;	n=5	and	8	for	MiD49	and	MiD51	respec)vely).	
(E)	miR-34a-3p	is	decreased	in	whole	blood	and	plasma	from	IPAH	pa0ents.	miR-34a-3p	expression	from	whole	blood	and	plasma	from	two	
cohorts	 were	 normalized	 to	 U6	 and	miR-23a-3p	 respec)vely,	 and	 analyzed	 by	 qRT-PCR	 	 (*P	 <	 0.05,	 ***P	 <	 0.001;	 n=11-29	 for	 healthy	
volunteer	and	n=14-39	for	IPAH	pa)ent).	
(F)	miR-34a-3p	 iden0ﬁed	pa0ents	with	 IPAH.	Receiver	opera)ng	 characteris)c	 (ROC)	 curves	 showing	 sensi)vity	 and	 speciﬁcity	of	whole	
blood	and	plasma	miR-34a-3p	for	diﬀeren)a)ng	pa)ents	with	IPAH	from	healthy	volunteers	at	the	)me	of	diagnosis	(Sheﬃeld	whole	blood:	
AUC=0.7857,	 P	 =	 0.0160;	 Beijing	 whole	 blood:	 AUC=0.807,	 P	 =	 0.0002;	 Sheﬃeld	 plasma:	 AUC=0.7573,	 P	 =	 0.0010;	 Beijing	 plasma:	
AUC=0.8846,	P	<	0.0001).	
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Fig.	5:	Increasing	expression	of	miR-34a-3p	downregulates	MiD49	and	MiD51	in	PAH	PASMC;	administering	an0-miR-34a-3p	upregulates	
MiD49	and	MiD51	in	normal	PASMC.	
(A)	Overexpression	of	miR-34a-3p	downregulates	MiD49	and	MiD51.	Representa)ve	 images	of	 immunoblots	and	densitometry	showing	
the	expressions	of	MiD49	and	MiD51	in	PAH	PASMC	transfected	with	miR-34a-3p.	Cells	were	transfected	with	miR-34a-3p	for	72h.	β-ac)n	
was	used	as	the	loading	control	(*P	<	0.05;	n=3-4/group).	
(B)	An0-miR-34a-3p	treatment	upregulates	MiD49	and	MiD51	in	normal	PASMC.	Representa)ve	images	of	immunoblots	and	densitometry	
showing	the	expressions	of	MiD49	and	MiD51	in	normal	human	PASMC	transfected	with	an)-miR-34a-3p	for	72h.	β-ac)n	was	used	as	the	
loading	control	(*P	<	0.05;	n=4/group).	
(C-H)	Overexpression	of	miR-34a-3p	inhibits	mitochondrial	ﬁssion,	cell	prolifera0on	and	induces	apoptosis	in	PAH	PASMC.		
(C)	Representa0ve	images	of	mitochondrial	networks	of	PAH	PASMC	transfected	with	miR-34a-3p	mimic.	The	cells	were	also	infected	with	
Adv-mNeon	 Green	 and	 imaged	 48h	 following	 infec)on.	 Mitochondria	 were	 color	 coded	 by	 their	 morphology:	 green:	 punctate;	 red:	
intermediate;	purple:	ﬁlamentous.	Scale	bar:	10μm.		
(D)	 Mitochondrial	 fragmenta0on	 was	 quan0ﬁed	 by	 mitochondrial	 fragmenta0on	 count	 (MFC)	 and	 percentage	 of	 area	 of	 punctate,	
intermediate	and	ﬁlamentous	mitochondria	(***P	<	0.001;	n=16-20/group).	
(E)	 Mitochondrial	 network	 is	 restored	 in	 PAH	 PASMC	 by	 augmen0ng	 miR-34a-3p.	 Representa)ve	 images	 of	 the	 photoac)va)on	
experiments	 conﬁrmed	 the	 increase	 in	mitochondrial	network	 in	PAH	PASMCs	co-transfected	with	miR-34a-3p	and	mitochondrial	matrix	
targeted	green	ﬂuorescent	protein	(mito-PAGFP)	for	48	h.	The	cells	were	also	loaded	with	the	poten)ometric	dye	TMRM	(red).	Scale	bar:	
10μm.	
(F)	 Quan0ﬁca0on	 of	 mitochondrial	 network	 in	 PAH	 PASMC	 by	 augmen0ng	 miR-34a-3p.	 Mitochondrial	 network	 is	 quan)ﬁed	 by	
determining	mitochondrial	networking	factor	(MNF)	which	is	increased	in	PAH	PAMC	following	transfec)on	with	miR-34a-3p	mimic.	(*P	<	
0.05;	n=6/group;	AU:	Arbitrary	unit).	
(G)	 Augmen0ng	 miR-34a-3p	 inhibits	 prolifera0on	 of	 PAH	 PASMC.	 Cell	 prolifera)on	 was	 analyzed	 72h	 following	 miR-34a-3p	 mimic	
transfec)on	in	PAH	PASMC	(*P	<	0.05;	n=3/group).	
(H)	Augmen0ng	miR-34a-3p	induces	apoptosis	of	PAH	PASMC.	PAH	PASMC	transfected	with	miR-34a-3p	mimic.	Apoptosis	was	assessed	by	
measuring	the	ac)vity	of	caspase3/7	48h	following	transfec)on	with	miR-34a-3p	mimic	(n=2	IPAH	PASMC	lines/group).	
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Fig.	6:	Demonstra0on	of	the	therapeu0c	relevance	of	the	miR-34a-3p-MiD	pathway	in	preclinical	PAH	model.	
(A)	Nebulized	siMiDs	regresses	monocrotaline-induced	PAH	(MCT	PAH).	Compared	to	control	rats,	MCT	PAH	rats	had	elevated	PAP,	RVSP	
and	decreased	CO,	as	determine	by	closed-chest	right	heart	catheteriza)on.	siMiD49	and	siMiD51	treatments	were	eﬀec)ve	in	decreasing	
PAP,	RVSP	and	increasing	CO	resul)ng	in	signiﬁcant	decrease	of	TPR	(*P	<	0.05,	**P	<	0.01,	***P	<	0.001,	****P	<	0.0001;	One	way	ANOVA,	
n=4-10/group).	
(B)	Augmen0ng	miR-34a-3p	regresses	MCT	PAH.	Decreased	PAP,	RVSP	and	increased	CO	resul)ng	in	signiﬁcant	decrease	of	TPR	(*P	<	0.05,	
**P	<	0.01,	***P	<	0.001,	****P	<	0.0001;	One-way	ANOVA,	n=4-10/group).		
(C)	Representa0ve	images	of	longitudinal	and	cross	sec0ons	of	small	pulmonary	arteries	and	summary	data	indica0ng	the	regression	of	
PAH	 caused	 by	 siMiD49	 or	 siMiD51	 or	 by	miR-34a-3p	mimic	was	 associated	with	 a	 decrease	 in	 the	wall	 thickness	 in	MCT	 PAH	 rats.	
Regression	 of	 PAH	 was	 assessed	 by	 measuring	 %	 of	 wall	 thickness	 by	 immunoﬂuorescence	 staining	 of	 smooth	 muscle	 ac)n	 and	 von	
Willebrand	Factor	(vWF)	(***P	<	0.001;	One-way	ANOVA,	n=4-5/group).		Scale	bar:	50μm.	
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Fig.	7:	Demonstra0on	of	the	therapeu0c	relevance	of	the	miR-34a-3p-MiD	pathway	in	preclinical	model.	
(A)	Representa)on	of	the	proposed	miR-MiDs	pathway	 in	PAH	rela)ve	to	normal.	 (B)	Decreased	expression	of	miR-34a-3p	 in	PAH	pa)ents	
leads	 to	 increased	 expression	 of	 the	 Drp1	 binding	 partners	MiD49	 and	MiD51	 which	 in	 turn	 increases	mito)c	 ﬁssion	 and	 promotes	 cell	
prolifera)on.	
